4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Operating Leases data on file, last reported at $15.0 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 17.19% year-over-year to $15.0 million in Q1 2026; TTM through Mar 2026 was $15.0 million, a 17.19% decrease from a year earlier, with the FY2025 full-year figure at $15.8 million, down 16.6% from the prior year.
• Operating Leases for Q1 2026 stood at $15.0 million, down from $15.8 million in the prior quarter.
• Over the last five years, Operating Leases for FDMT reached as high as $19.7 million in Q3 2024 and fell as low as $10.5 million in Q2 2024.
• Historically, Operating Leases has averaged $14.6 million across 5 years, with a median of $14.4 million in 2022.
• Across the five-year window, Operating Leases soared 65.93% in 2025 and retreated 17.19% in 2026, its largest moves.
• Year by year, Operating Leases stood at $13.5 million in 2022, then retreated by 14.46% to $11.5 million in 2023, then jumped by 64.63% to $19.0 million in 2024, then decreased by 16.6% to $15.8 million in 2025, then dropped by 4.88% to $15.0 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $15.0 million in Q1 2026, $15.8 million in Q4 2025, and $16.6 million in Q3 2025.